Pegarginase - Bio-Cancer Treatment International

Drug Profile

Pegarginase - Bio-Cancer Treatment International

Alternative Names: BCT-100; PEG-arginase - Bio-Cancer Treatment International; PEG-BCT-100; PEGylated recombinant human arginase - Bio-Cancer Treatment International; Recombinant human arginase 1 - Bio-Cancer Treatment International; Recombinant human arginase I - Bio-Cancer Treatment International; rhArg1 - Bio-Cancer Treatment International; rhArgI - Bio-Cancer Treatment International; rhArgIpeg5000

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bio-Cancer Treatment International
  • Class Antineoplastics; Polyethylene glycols; Ureohydrolases
  • Mechanism of Action Arginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Hepatocellular carcinoma
  • Suspended Leukaemia; Lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 06 Mar 2018 University of Birmingham plans the phase I/II PARC trial for Cancer (Late-stage disease, Second-line therapy or greater) (IV, Infusion) (NCT03455140)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 27 Jul 2017 Bio-Cancer Treatment International Limited terminates a phase II trial for futility in Hepatocellular carcinoma (Monotherapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in Hong Kong (IV) (NCT02089763)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top